Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic announces leadership roster for post-Covidien merger; Allergan raises outlook; says Valeant offer undervalues company; EuroZone anti-trust regulators to rule next month on $43B Covidien buy; Steris to buy UK's Synergy Health, tax savings eyed; Bioventus bolsters bone healing lineup
Covidien says a connector compatibility issue between its Medi-Trace Cadence and Kendall electrodes and Philips defibrillators may have contributed to the death of a patient.
The European Commission's anti-trust regulators are slated next month to give their decision on Medtronic's $43 billion acquisition of Covidien.
Here's a look at some of the top legal news stories for medical device companies this week: Shareholder sues Medtronic over plan to cover execs' $58m tax tab; Report: Bard's mesh settlement is worth $21m; Covidien's Ev3 logs a pair of legal wins over Appriva, whistleblower; BD loses bid to overturn $114m antitrust loss to Retractable Technologies; Ex-Oriole DeCinces fights insider trading charges
The FDA green-lights Covidien's Nellcor portable SpO2 monitor for home use in adults and infants.
The FDA gave the green light to Covidien's (NYSE:COV) Nellcor portable SpO2 monitor, which is used to monitor oxygen and pulse levels in the home.
Medtronic reveals the leadership team slated to lead the company after its mega-merger with Covidien.
Covidien's Ev3 subsidiary logs a pair of legal wins, with the Delaware Supreme Court reversing a $250 million loss to Appriva and a Massachusetts federal judge tossing a whistleblower's lawsuit.